Anneyuko I Saito1, Tatsuya Inoue2, Makiko Kinoshita3, Takahiro Kosaka3, Taira Mitsuhashi3. 1. Department of Radiation Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan. anyusaike@yahoo.co.jp. 2. Department of Radiation Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan. 3. Department of Radiology, Juntendo Univeristy Urayasu Hospital, Chiba, Japan.
Abstract
BACKGROUND: Re-irradiation of a previously irradiated site must be done with careful consideration to minimize dose to organs at risk. AIMS: To evaluate pain response and safety of Sr-89 administration for painful bone metastases after prior irradiation. METHODS: We retrospectively reviewed patients with Sr-89 injection for painful bone metastasis in a previously irradiated site. All patients were seen in follow-up at 1, 2, 3, and 4 months after injection and every 6 months thereafter. Pain control, toxicity, and pain progression-free survival were analyzed. Correlation of pain relapse with the following characteristics was analyzed: gender, age, primary tumor, tumor pathology, baseline performance status, and baseline verbal rating scale. RESULTS: Among 25 patients analyzed (10 male, 15 female), median age was 68 (range, 50-81) years. Primary tumor sites included lung (n = 11), breast (n = 3), uterine cervix (n = 3), prostate (n = 3), and others (n = 5). Median follow-up was 25 (range, 1-76) months. Pain relief was observed in 24 patients (96.0%). One- and 2-year pain progression-free survival rates in these patients were 54.5% and 48.4%, respectively. Median time to pain progression was 5 (range, 2-16) months. Statistically significantly lower pain progression-free survival was observed in patients with osteolytic bone metastases (p < 0.01). No grade 3 or worse adverse events were observed. CONCLUSION: Sr-89 injection showed pain relief in most of our patients with painful bone metastases in a previously irradiated site and caused no grade 3 or worse adverse events. Sr-89 is an option for patients with a painful bone metastasis in a previously irradiated site.
BACKGROUND: Re-irradiation of a previously irradiated site must be done with careful consideration to minimize dose to organs at risk. AIMS: To evaluate pain response and safety of Sr-89 administration for painful bone metastases after prior irradiation. METHODS: We retrospectively reviewed patients with Sr-89 injection for painful bone metastasis in a previously irradiated site. All patients were seen in follow-up at 1, 2, 3, and 4 months after injection and every 6 months thereafter. Pain control, toxicity, and pain progression-free survival were analyzed. Correlation of pain relapse with the following characteristics was analyzed: gender, age, primary tumor, tumor pathology, baseline performance status, and baseline verbal rating scale. RESULTS: Among 25 patients analyzed (10 male, 15 female), median age was 68 (range, 50-81) years. Primary tumor sites included lung (n = 11), breast (n = 3), uterine cervix (n = 3), prostate (n = 3), and others (n = 5). Median follow-up was 25 (range, 1-76) months. Pain relief was observed in 24 patients (96.0%). One- and 2-year pain progression-free survival rates in these patients were 54.5% and 48.4%, respectively. Median time to pain progression was 5 (range, 2-16) months. Statistically significantly lower pain progression-free survival was observed in patients with osteolytic bone metastases (p < 0.01). No grade 3 or worse adverse events were observed. CONCLUSION: Sr-89 injection showed pain relief in most of our patients with painful bone metastases in a previously irradiated site and caused no grade 3 or worse adverse events. Sr-89 is an option for patients with a painful bone metastasis in a previously irradiated site.
Authors: Edward Chow; Peter Hoskin; Gunita Mitera; Liang Zeng; Stephen Lutz; Daniel Roos; Carol Hahn; Yvette van der Linden; William Hartsell; Eshwar Kumar Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-12 Impact factor: 7.038
Authors: Ahmed Hashmi; Matthias Guckenberger; Ron Kersh; Peter C Gerszten; Frederick Mantel; Inga S Grills; John C Flickinger; John H Shin; Daniel K Fahim; Brian Winey; Kevin Oh; B C John Cho; Daniel Létourneau; Jason Sheehan; Arjun Sahgal Journal: J Neurosurg Spine Date: 2016-06-24
Authors: Edward Chow; Yvette M van der Linden; Daniel Roos; William F Hartsell; Peter Hoskin; Jackson S Y Wu; Michael D Brundage; Abdenour Nabid; Caroline J A Tissing-Tan; Bing Oei; Scott Babington; William F Demas; Carolyn F Wilson; Ralph M Meyer; Bingshu E Chen; Rebecca K S Wong Journal: Lancet Oncol Date: 2013-12-23 Impact factor: 41.316